Table 1.
A) Size and PDI liposome composition | CLs Size (nm) PDI |
Lipoplexes (NP3) Size (nm) PDI |
Lipoplexes (NP5) Size (nm) PDI |
Lipoplexes (NP7) Size (nm) PDI |
---|---|---|---|---|
DOTAP/DOPE | 170±3.2 0.2±0.03 | 186±1.7 0.2±0.05 | 226±4.3 0.2±0.04 | 291±6.8 0.1±0.04 |
DOTAP/DOPE/DSPE-PEG | 167±2.5 0.2±0.04 | 178±3.4 0.2±0.06 | 217±5.4 0.2±0.04 | 265±4.5 0.1±0.03 |
DOTAP/Cholesterol | 145±2.6 0.1±0.03 | 176±2.5 0.2±0.06 | 238±3.5 0.1±0.05 | 281±5.6 0.2±0.03 |
DOTAP/Cholesterol/Chol-PEG | 132±4.3 0.2±0.06 | 166±3.5 0.1±0.04 | 226±6.2 0.2±0.07 | 279±3.8 0.2±0.03 |
DOTAP/Cholesterol/DSPE-PEG | 138±3.3 0.2±0.08 | 180±3.3 0.1±0.03 | 231±2.6 0.2±0.03 | 283±4.4 0.2±0.03 |
DOTAP/DOPE/Cholesterol | 174±2.5 0.1±0.02 | 190±2.4 0.2±0.02 | 219±4.4 0.2±0.03 | 255±4.3 0.1±0.03 |
DOTAP/DOPE/Cholesterol/DSPE-PEG | 171±3.4 0.2±0.06 | 186±2.6 0.1±0.07 | 218±3.5 0.1±0.02 | 253± 3.4 0.2±0.03 |
B) Zeta potential liposome composition |
CLs Zeta (mV) |
Lipoplexes (N/P 3) Zeta (mV) |
Lipoplexes (N/P 5) Zeta (mV) |
Lipoplexes (N/P 7) Zeta (mV) |
DOTAP/DOPE | 44±0.2 | 40±0.2 | 47±0.3 | 50±0.1 |
DOTAP/DOPE/DSPE-PEG | 28±0.4 | 25±0.3 | 32±0.1 | 37±0.7 |
DOTAP/Cholesterol | 40±0.3 | 37±0.6 | 42±0.1 | 50±0.3 |
DOTAP/Cholesterol/Chol-PEG | 27±0.1 | 22±0.1 | 28±0.3 | 35±0.3 |
DOTAP/Cholesterol/DSPE-PEG | 26±0.7 | 22±0.3 | 31±0.2 | 39±0.5 |
DOTAP/DOPE/Cholesterol | 41±0.2 | 34±0.2 | 39±0.6 | 45±0.2 |
DOTAP/DOPE/Cholesterol/DSPE-PEG | 35±0.4 | 28±0.3 | 34±0.1 | 39±0.6 |
DOTAP/DOPE/Cholesterol/Chol-PEG | 38±0.3 | 30±0.2 | 37±0.4 | 43±0.3 |
Abbreviations: PDI, polydispersity index; DOTAP, (1,2-dioleoyl-3-trimethylammoniumpropane); DOPE, (dioleoylphosphatidylethanolamine); DSPE-PEG, (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)]).